Lomustine is beneficial to older AML with ELN2017 adverse risk profile and intermediate karyotype: a FILO study.

doi:10.1038/s41375-020-01031-1

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Lomustine is beneficial to older AML with ELN2017 adverse risk profile and intermediate karyotype: a FILO study.

Leukemia - 1 May 2021

Largeaud Laetitia, Cornillet-Lefebvre Pascale, Hamel Jean-François, Dumas Pierre-Yves, Prade Naïs, Dufrechou Stéphanie, Plenecassagnes Julien, Luquet Isabelle, Blanchet Odile, Banos Anne, Béné Marie C, Bernard Marc, Bertoli Sarah, Bonmati Caroline, Fornecker Luc Matthieu, Guièze Romain, Haddaoui Lamya, Hunault Mathilde, Ianotto Jean Christophe, Jourdan Eric, Ojeda Mario, Peterlin Pierre, Vey Norbert, Zerazhi Hacene, Yosr Hicheri, Mineur Ariane, Cahn Jean-Yves, Ifrah Norbert, Récher Christian, Pigneux Arnaud, Delabesse Eric

Abstract excerpt

We previously reported the benefit of lomustine addition to conventional chemotherapy in older acute myeloid leukemias with nonadverse chromosomal aberrations in the LAM-SA 2007 randomized clinical trial (NCT00590837). A molecular analysis of 52 genes performed in 330 patients included in this trial, 163 patients being treated with lomustine in combination with idarubicin and cytarabine and 167 without lomustine,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents, Alkylating

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Chromosome Aberrations

Share to Cytarabine

Share to Cytogenetics

Share to Karyotype

Share to Karyotyping

Share to Leukemia, Myeloid, Acute

Share to Nucleophosmin

Source

Open in PubMed

Identifiers

PMID: 32943750
DOI: 10.1038/s41375-020-01031-1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Lomustine is beneficial to older AML with ELN2017 adverse risk profile and intermediate karyotype: a FILO study.PMID 32943750Read ↗

Added prognostic value of secondary AML-like gene mutations in ELN intermediate-risk older AML: ALFA-1200 study results.Semantic proximity Read ↗

Genetic identification of patients with AML older than 60 years achieving long-term survival with intensive chemotherapy.Semantic proximity Read ↗

Beat-AML 2024 ELN-refined risk stratification for older adults with newly diagnosed AML given lower-intensity therapy.Semantic proximity Read ↗

Molecular classification and prognosis in younger adults with acute myeloid leukemia and intermediate-risk cytogenetics treated or not by gemtuzumab ozogamycin: Final results of the GOELAMS/FILO acute myeloid leukemia 2006-intermediate-risk trial.Semantic proximity Read ↗

A scoring system for AML patients aged 70 years or older, eligible for intensive chemotherapy: a study based on a large European data set using the DATAML, SAL, and PETHEMA registries.Semantic proximity Read ↗

Validation and refinement of the revised 2017 European LeukemiaNet genetic risk stratification of acute myeloid leukemia.Semantic proximity Read ↗

A precision medicine classification for treatment of acute myeloid leukemia in older patients.Semantic proximity Read ↗

Genetics of acute myeloid leukemia in the elderly: mutation spectrum and clinical impact in intensively treated patients aged 75 years or older.Semantic proximity Read ↗

ELN 2017 classification significantly impacts the risk of early death in acute myeloid leukemia patients receiving intensive induction chemotherapy.Semantic proximity Read ↗

Latest Insights and Progress in the Clinical Management of Elderly Patients with Acute Myeloid Leukemia: From Genetic Advancements to Targeted TreatmentsSemantic proximity Read ↗

Genetic risk classification for adults with AML receiving less-intensive therapies: the 2024 ELN recommendations.Semantic proximity Read ↗

Age-dependent clinical, molecular, and prognostic differences in patients with AML: a retrospective study.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.